Navigation Links
Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins
Date:9/3/2008

SYDNEY, Australia, Sept. 4 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that it has enrolled the first subject into its second pivotal Phase 3 clinical trial evaluating Bronchitol in cystic fibrosis sufferers.

The Phase 3 trial is being conducted in 41 hospitals across North America, Argentina and Germany, and is the final clinical step before Pharmaxis seeks approval to market Bronchitol for cystic fibrosis in the United States.

Pharmaxis Chief Executive Officer Dr Alan Robertson said: "We are delighted to commence this trial following helpful discussions with the FDA and with assistance from the U.S. Cystic Fibrosis Foundation. This trial follows the recent closure to recruitment of the first Phase 3 trial involving 325 subjects. Bronchitol has been awarded fast-track status in the U.S., and orphan drug designation in both the U.S. and EU and we look forward to bringing Bronchitol to the international cystic fibrosis community as rapidly as we can."

This trial is being conducted under the Food and Drug Administration's Special Protocol Assessment (SPA) scheme. The SPA process ensures the clinical trial protocol is acceptable to the U.S. FDA when the results are submitted to support a marketing application for Bronchitol.

The Phase III clinical trial is designed to include a 26-week efficacy treatment period, followed by a 26-week safety period. The efficacy component of the trial is a randomized, double-blind investigation of Bronchitol twice daily in approximately 300 patients with cystic fibrosis. The trial is enrolling cystic fibrosis patients aged six years and older. Participants will be assessed for improvements in lung function, infectious episodes, antibiotic use, quality of life and a range of health economic measures. Further details concerning the trial are available at

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated With Second-Generation TAXUS(R) Liberte(R) Stent
2. Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial
3. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
4. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
5. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
6. Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen
7. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
8. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
9. Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... MYERS, Fla. , Jan. 23, 2015  Today the ... of Novartis, Bexsero® for the prevention of serogroup ... 25. Bexsero and Pfizer,s vaccine Trumenba®, which received FDA ... helping prevent this devastating disease. "I ...
(Date:1/23/2015)... Iowa , Jan. 23, 2015  The Partnership to Fight Chronic ... health care leaders and a new study analyzing the ... The PFCD is a nationwide coalition working to educate policy makers ... released at the Capitol was focused on how the ...
(Date:1/23/2015)... 23, 2015 More than a third of reproductive-aged women ... with private insurance, filled a prescription for an opioid pain ... this week,s Morbidity and Mortality Weekly Report (MMWR). ... treat moderate to severe pain.  They are also found in ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... Feb. 17 The United States, fifth hand ... home to Massena, New York this week after ... of Kleinert Kutz and University of Louisville ... UofL hand surgeons performed the Hondusky,s hand transplant ...
... Sanofi Pasteur, the,vaccines division of sanofi-aventis Group (EURONEXT ... is sponsoring a phase II clinical study of a ... causes of,hospital-acquired infection in Europe and North America. , ... the United Kingdom is investigating the,safety and efficacy of ...
Cached Medicine Technology:Fifth U.S. Hand Transplant Patient Heads Home to NY 2Fifth U.S. Hand Transplant Patient Heads Home to NY 3Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile 2Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile 3Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile 4Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile 5
(Date:1/22/2015)... January 22, 2015 Padre Murphy's and Owner ... of Pro Player Health Alliance (PPHA). The PPHA's ... in getting everyone, including NFL greats, treated for obstructive sleep ... leading groups supporting the cause in the valley. The most ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 The Incredible ... Bodybuilder Ben Pakulski to increase lean muscle by up to ... has caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an ... that it is a step-by-step, scientific diet formula that allows ...
(Date:1/22/2015)... 22, 2015 Blue Cross and Blue Shield ... exemplify what it means to “Live Fearless.” , ... to share their stories about how they or someone they ... others by living in the moment. By telling these types ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... ... everyone will carry their snacks while on the go. KUBBE is the first and ... hassle free. , ... 17, 2010 -- KUBBE is a trendy plastic utility buckle that allows people to carry ...
... , , ... ... ... ...
... ... ... ... ...
... in the March issue of Radiology , researchers from ... have determined that an imaging exam of the heart using ... much as 91 percent less radiation than standard helical CT ... in recent years, due to its diagnostic accuracy in assessing ...
... ... ... ... ...
... ... ... ... , ...
Cached Medicine News:Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 2Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 3Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 4Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 5Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 6Health News:Pew Report: New Jersey Failing to Address Children's Dental Health Crisis 7Health News:Pew Report: Connecticut is a National Leader in Addressing Children's Dental Health 2Health News:Pew Report: Connecticut is a National Leader in Addressing Children's Dental Health 3Health News:Pew Report: Connecticut is a National Leader in Addressing Children's Dental Health 4Health News:Pew Report: Connecticut is a National Leader in Addressing Children's Dental Health 5Health News:Pew Report: Connecticut is a National Leader in Addressing Children's Dental Health 6Health News:Pew Report: Connecticut is a National Leader in Addressing Children's Dental Health 7Health News:New cardiac CT technology drastically reduces patient radiation exposure 2Health News:E-Cigarette Maker Green Smoke Tells FDA to Back Off! 2Health News:E-Cigarette Maker Green Smoke Tells FDA to Back Off! 3Health News:E-Cigarette Maker Green Smoke Tells FDA to Back Off! 4Health News:Healthcare Realty Trust Announces Fourth Quarter Results 2Health News:Healthcare Realty Trust Announces Fourth Quarter Results 3Health News:Healthcare Realty Trust Announces Fourth Quarter Results 4Health News:Healthcare Realty Trust Announces Fourth Quarter Results 5Health News:Healthcare Realty Trust Announces Fourth Quarter Results 6Health News:Healthcare Realty Trust Announces Fourth Quarter Results 7Health News:Healthcare Realty Trust Announces Fourth Quarter Results 8Health News:Healthcare Realty Trust Announces Fourth Quarter Results 9Health News:Healthcare Realty Trust Announces Fourth Quarter Results 10Health News:Healthcare Realty Trust Announces Fourth Quarter Results 11Health News:Healthcare Realty Trust Announces Fourth Quarter Results 12Health News:Healthcare Realty Trust Announces Fourth Quarter Results 13Health News:Healthcare Realty Trust Announces Fourth Quarter Results 14Health News:Healthcare Realty Trust Announces Fourth Quarter Results 15
Extremely fine straight....
Curved delicate 5 mm blades....
Micro dressing forceps....
... M520 OH3 is a smart ... performance available on the market ... stand. The Leica M520 OH3 ... greatest range of movement and ...
Medicine Products: